Abstract 5734
Background
Despite high sensitivity to first-line chemotherapy (CT), most small-cell lung cancer (SCLC) patients relapse. Efficacy of 2nd-line CT is modest and influenced by treatment-free-interval (TFI). Topotecan demonstrated modest activity and significant haematological toxicity. Paclitaxel-based regimens showed to be active in this setting. Nab-paclitaxel, compared to paclitaxel, has a reduced incidence of hypersensitivity reactions and of neutropenia. Safety and efficacy in relapsed SCLC have not been prospectively studied.
Methods
This open-label phase II study enrolled patients with extensive- (ED) or limited-disease (LD) SCLC progressed during or after etoposide/platinum-based 1st-line CT with the aim to assess the activity and safety of Nab-paclitaxel. Patients were classified as refractory (TFI < 60 days) or sensitive (TFI ≥ 60 days). Eligible patients received Nab-paclitaxel 100 mg/mq on days 1,8,15 every 28 days for 6 cycles, progressive disease or intolerable toxicity. Computed tomography scan was performed every 2 cycles. Treatment could be continued beyond the 6th cycle in presence of prolonged response, clinical benefit and good tolerance to drug. The primary endpoint was objective response, evaluated according to RECIST v1.1 criteria. The secondary endpoints were toxicity, measured according to NCI-CTCAE v4.03, progression-free and overall survival.
Results
From January 2017 to March 2018, 68 patients (25 refractory and 43 sensitive) were enrolled in the modified intentiontotreat population. Median age was 68.5 years (range 44-80). 44 patients were males and 57 had ED. Median follow-up was 5.8 months (IQR 3.37.1). Objective responses are currently being reviewed by an independent radiology panel. Most common toxicities (of all grades) were anemia (39%), leukopenia (27%), neutropenia (28%), nausea (19%), diarrhoea (21%), fatigue (52%), peripheral neuropathy (19%). The only severe toxicity (grade ≥3) was neutropenia (9%). In 13 patients treatment is still ongoing while 3/55 (5%) patients discontinued treatment for toxicity.
Conclusions
This is the first prospective study of Nab-paclitaxel for relapsed SCLC. Nab-paclitaxel demonstrated a manageable toxicity profile. Final activity data will be available for the meeting.
Clinical trial identification
EudraCT: 2016-000408-27; NCT03219762.
Legal entity responsible for the study
GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica).
Funding
Celgene.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract